3D Bioprinted Immunomodulation─The Advancing Landscape of Next-Generation Immuno-oncology
- PMID: 40444674
- DOI: 10.1021/acs.biomac.4c01816
3D Bioprinted Immunomodulation─The Advancing Landscape of Next-Generation Immuno-oncology
Abstract
Tumor microenvironment (TME) alteration can lead to tumorigenesis, where tumors evade the immune system and spread. Thus, immunomodulation inside the TME may be a useful therapeutic approach. In this regard, bioprinting has become a potential technique for developing therapeutic solutions that offer improved control over immune modulation. Through the use of novel immune cell therapies and realistic tumor models, it provides a platform for advancing cancer immunotherapy. By examining the complex mechanisms of immunomodulation in tumorigenesis, this review article clarifies how interactions between the immune system and the tumor microenvironment affect the initiation and spread of cancer. Additionally, the effectiveness of 3D bioprinting in modulating and activating immune cells, such as T cells, dendritic cells, and macrophages, has also been analyzed. A summary of current research shows the pivotal role of 3D bioprinting in establishing a solid foundation for advancing anticancer studies and revolutionizing cancer treatment through immunotherapeutic strategies.
Similar articles
-
3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment.Cell Oncol (Dordr). 2024 Aug;47(4):1113-1126. doi: 10.1007/s13402-024-00935-9. Epub 2024 Mar 23. Cell Oncol (Dordr). 2024. PMID: 38520648 Free PMC article. Review.
-
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies.Int J Mol Sci. 2025 Mar 24;26(7):2923. doi: 10.3390/ijms26072923. Int J Mol Sci. 2025. PMID: 40243502 Free PMC article. Review.
-
Advancing tumor microenvironment and lymphoid tissue research through 3D bioprinting and biofabrication.Adv Drug Deliv Rev. 2025 Feb;217:115485. doi: 10.1016/j.addr.2024.115485. Epub 2024 Dec 7. Adv Drug Deliv Rev. 2025. PMID: 39653084 Review.
-
Recapitulating the Cancer-Immunity Cycle on a Chip.Adv Healthc Mater. 2025 Jan;14(1):e2401927. doi: 10.1002/adhm.202401927. Epub 2024 Sep 2. Adv Healthc Mater. 2025. PMID: 39221688 Review.
-
Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling.Biofabrication. 2022 May 31;14(3). doi: 10.1088/1758-5090/ac6d11. Biofabrication. 2022. PMID: 35512666 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical